Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
Capricor Therapeutics fell over 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.
Capricor's stock dropped a lot after the FDA shared documents about an upcoming meeting to review one of the company's medicines. When people see FDA documents before a big review, they're trying to understand if regulators have concerns, which can make investors nervous.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.